Quantify’s Mathias Lilja and Johan Mesterton are co-authors on a new study on cytarabine dosing for treating secondary and high-risk AML using a synthetic control arm study design.
Since 1980’s, the standard treatment of acute myeloid leukemia (AML) is cytarabine infusion […]
In December 2023, Quantify’s Stuti Arya, Nicholas Norton and Puneet Kaushik published a study assessing recent changes to adult national immunization programs for pneumococcal vaccination and attempting to determine how those changes impacted coverage in European Adults. The review revealed […]
In April 2024, Quantify’s Helena Skröder and Nicholas Norton published a study quantifying the burden of acute otitis media (AOM) caused by pneumoniae, after widespread use of PCVs. The review found […]
Quantify Research is recognized as one of the 10 most cited publications last year in the renowned journal Alzheimer’s & Dementia!
Our work with Project Alzheimer Value Europe titled “Global estimates on the number of […]
Make sure you’ve read Quantify’s CEO Kirk Geale‘s PharmaTimes article published late last year, explaining how global pharmaceutical executives can harness the power of Scandinavian health data to achieve regulatory and commercial success.
In Quantify’s latest publication co-authored by Christoph Abé, PhD, the research group conducted a field trial focused on the ICD-11 chapter on mental disorders which contains new diagnoses for impulse control disorders.
Using a vignette-based methodology, this field study […]
To peck someone…again! Luckily in this case, the world of medical coding has us covered with the (hopefully) rare yet precise ICD code W61.32XD “Struck by a chicken, subsequent encounter.”
Although this rare event has a diagnosis code, not all diseases […]
Check out the latest issue of PharmaTimes Magazine, where our CEO Kirk Geale explains how global pharmaceutical executives can harness the power of Nordic health data.
Nordic RWD are globally unique and practitioners should not miss the opportunities available […]
In our latest publication in the Journal of Medical Economics, the cost-effectiveness of bimekizumab was assessed for the treatment of psoriatic arthritis in Sweden in collaboration with UCB and others.
According to Quantify Research co-author and payer expert Linnea […]